Clinical impact of 18F‐FDG positron emission tomography/CT on adenoid cystic carcinoma of the head and neck. Issue 3 (11th October 2016)

• Record Type: Journal Article
• Authors: Jung, Ji‐hoon; Lee, Sang‐Woo; Son, Seung Hyun; Kim, Choon‐Young; Lee, Chang‐Hee; Jeong, Ju Hye; Jeong, Shin Young; Ahn, Byeong‐Cheol; Lee, Jaetae
• Is Part Of: Head & neck. Volume 39:Issue 3(2017)
• Page Start: 447
• Page End: 455
• Publication Date: 2016-10-11
• Subjects: adenoid cystic carcinoma -- 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT -- metabolic positron emission tomography (PET) parameters -- staging -- progression‐free survival; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.24605
• Languages: English
• ISSNs: 1043-3074

Abstract

ABSTRACT: Background: The purpose of this retrospective study was to assess the diagnostic value of 18 F‐fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and the prognostic value of metabolic PET parameters in patients with adenoid cystic carcinoma of the head and neck (ACCHN). Methods: Forty patients with newly diagnosed ACCHN were enrolled in this study. We investigated the diagnostic value of 18 F‐FDG PET/CT for detecting and staging compared to conventional CT. Kaplan–Meier survival analysis for progression‐free survival (PFS) was performed with clinicopathological factors and metabolic PET parameters. Results: The 18 F‐FDG PET/CT showed comparable sensitivity (92.3%) to conventional CT for lesion detection, and changed staging and management plan in 6 patients (15.0%). Lower PFS rates were associated with advanced T classification, advanced TNM classification, high maximum standardized uptake value (SUVmax; >5.1), and high total lesion glycolysis (>40.1) of the primary tumor. Conclusion: The 18 F‐FDG PET/CT can provide additional information for initial staging, and metabolic PET parameters may serve as prognostic factors of ACCHN. © 2016 Wiley Periodicals, Inc. Head Neck 39: 447–455, 2017